Received Apr 30, 2026
Reports are unverified and do not show that a vaccine caused an event. Full disclaimer
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPA | HEP A (HAVRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | MZ474 | — |
child dose of Havrix was administered to an adult patient; Administration of less than the recommended dose; This non-serious case was reported by a other health professional via call center representative and described the occurrence of adult use of a child product in a 21-year-old male patient who received HAV (Havrix 720) (batch number MZ474, expiry date 24-APR-2026) for prophylaxis. Previously administered products included Havrix 720 (received the first dose of Havrix 720). On 20-APR-2026, the patient received the 2nd dose of Havrix 720. On 20-APR-2026, an unknown time after receiving Havrix 720, the patient experienced adult use of a child product (Verbatim: child dose of Havrix was administered to an adult patient) and underdose (Verbatim: Administration of less than the recommended dose). The outcome of the adult use of a child product and underdose were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.